σ Receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation

Pharmacological Reports

Volumn 65, Issue 2, 2013, Pages 343-349

  Robson, Matthew J ^a   Seminerio, Michael J ^a   McCurdy, Christopher R ^b   Coop, Andrew ^c   Matsumoto, Rae R ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Hyperthermia; Methamphetamine; Neurotoxicity; receptor

Indexed keywords

3 [4 (4 CYCLOHEXYLPIPERAZIN YL)PENTYL] 6 FLUOROBENZO[D]THIAZOL 2(3H) ONE; AC 927; AZ 66; DOPAMINE; METHAMPHETAMINE; N PHENETHYLPIPERIDINE OXALATE; OPIATE ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORE TEMPERATURE; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DRUG ACTIVITY; HYPERTHERMIA; IN VIVO STUDY; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHARMACOLOGICAL BLOCKING;

EID: 84879373727     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71009-0     Document Type: Article

References (22)

1. Albers DS, Sonsalla PK: Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther, 1995, 275, 1104-1114.
2. Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W, Jr., Holson RR: Further studies of the role of hyperthermia in methamphetamine neurotoxicity . J Pharmacol Exp Ther, 1994, 268, 1571-1580.
3. Bowyer JF, Tank AW, Newport GD, Slikker W, Jr., Ali SF, Holson RR: The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther, 1992, 260, 817-824.
4. Callaghan RC, Cunningham JK, Sykes J, Kish SJ: Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend, 2012, 120, 35-40.
5. Chipana C, Torres I, Camarasa J, Pubill D, Escubedo E: Memantine protects against amphetamine derivativesinduced neurotoxic damage in rodents. Neuropharmacology, 2008, 54, 1254-1263.
6. Escubedo E, Camarasa J, Chipana C, Garcia-Rates S, Pubill D: Involvement of nicotinic receptors in methamphetamine-And MDMA-induced neurotoxicity: pharmacological implications. Int Rev Neurobiol, 2009, 88, 121-166.
7. Gonzalez-Alvear GM,Werling LL: Regulation of [3H]dopamine release from rat striatal slices by sigma receptor ligands. J Pharmacol Exp Ther, 1994, 271, 212-219.
8. Kaushal N, Elliott M, Robson MJ, Iyer AK, Rojanasakul Y, Coop A, Matsumoto RR: AC927, a s receptor ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells. Mol Pharmacol, 2012, 81, 299-308.
9. Kaushal N, McCurdy CR, Matsumoto RR: SN79 attenuates the neurotoxic effect of methamphetamine: In vivo and in vitro studies. Society for Neuroscience, 2011, 2011 Neuroscience Meeting Planner.
10. Kaushal N, Seminerio MJ, Shaikh J, Medina MA, Mesangeau C, Wilson LL, McCurdy CR, Matsumoto RR: CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic effects of methamphetamine in mice. Neuropharmacology, 2011, 61, 992-1000.
11. Kiyatkin EA, Sharma HS: Acute methamphetamine intoxication: brain hyperthermia, blood-brain barrier, brain edema, and morphological cell abnormalities. Int Rev Neurobiol, 2009, 88, 65-100.
12. Krasnova IN, Cadet JL: Methamphetamine toxicity and messengers of death. Brain Res Rev, 2009, 60, 379-407.
13. Liu X, Nuwayhid S, Christie MJ, Kassiou M, Werling LL: Trishomocubanes: novel s-receptor ligands modulate amphetamine-stimulated [3H]dopamine release. Eur J Pharmacol, 2001, 422, 39-45.
14. Maeda DY, Williams W, Kim WE, Thatcher LN, Bowen WD, Coop A: N-Arylalkylpiperidines as high-Affinity sigma-1 and sigma-2 receptor ligands: phenylpropylamines as potential leads for selective sigma-2 agents. Bioorg Med Chem Lett, 2002, 12, 497-500.
15. Matsumoto RR, Shaikh J, Wilson LL, Vedam S, Coop A: Attenuation of methamphetamine-induced effects through the antagonism of sigma (s) receptors: Evidence from in vivo and in vitro studies. Eur Neuropsychopharmacol, 2008, 18, 871-881.
16. Nguyen EC, McCracken KA, Liu Y, Pouw B, Matsumoto RR: Involvement of sigma (s) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology, 2005, 49, 638-645.
17. Rawson RA, Condon TP: Why do we need an addiction supplement focused on methamphetamine? Addiction, 2007, 102 Suppl 1, 1-4.
18. Seminerio MJ, Kaushal N, Shaikh J, Huber JD, Coop A, Matsumoto RR: Sigma (s) receptor ligand, AC927 (N-phenethylpiperidine oxalate), attenuates methamphetamine-induced hyperthermia and serotonin damage in mice. Pharmacol Biochem Behav, 2011, 98, 12-20.
19. Seminerio MJ, Robson MJ, Abdelazeem AH, Mesangeau C, Jamalapuram S, Avery BA, McCurdy CR, Matsumoto RR: Synthesis and pharmacological characterization of a novel sigma receptor ligand with improved metabolic stability and antagonistic effects against methamphetamine . AAPS J, 2012, 14, 43-51.
20. Shioda N, Ishikawa K, Tagashira H, Ishizuka T, Yawo H, Fukunaga K: Expression of a truncated form of the endoplasmic reticulum chaperone protein, s1 receptor, promotes mitochondrial energy depletion and apoptosis. J Biol Chem, 2012, 287, 23318-23331.
21. Tsuji T, Asanuma M, Miyazaki I, Miyoshi K, Ogawa N: Reduction of nuclear peroxisome proliferator-Activated receptor g expression in methamphetamine- induced neurotoxicity and neuroprotective effects of ibuprofen. Neurochem Res, 2009, 34, 764-774.
22. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ et al.: Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci, 2001, 21, 9414-9418.